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Abstract
Background: Most patients with ductal pancreatic adenocarcinoma are diagnosed with locally
advanced (unresectable) or metastatic disease. The aim of this study was to evaluate the prognostic
significance of DNA ploidy in relation with established clinical and laboratory variables in such
patients.
Methods:  Two hundred and twenty six patients were studied retrospectively. Twenty two
potential prognostic variables (demographics, clinical parameters, biochemical markers, treatment
modality) were examined.
Results: Mean survival time was 38.41 weeks (95% c.i.: 33.17–43.65), median survival 27.00 weeks
(95% c.i.: 23.18–30.82). On multivariate analysis, 10 factors had an independent effect on survival:
performance status, local extension of tumor, distant metastases, ploidy score, anemia under
epoetin therapy, weight loss, pain, steatorrhoea, CEA, and palliative surgery and chemotherapy.
Patients managed with palliative surgery and chemotherapy had 6.7 times lower probability of death
in comparison with patients without any treatment. Patients with ploidy score > 3.6 had 5.0 times
Published: 31 July 2009
BMC Cancer 2009, 9:264 doi:10.1186/1471-2407-9-264
Received: 30 January 2009
Accepted: 31 July 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/264
© 2009 Tsavaris et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
Page 2 of 11
(page number not for citation purposes)
higher probability of death in comparison with patients with ploidy score < 2.2 and these with
ploidy score 2.2–3.6 had 6.3 times higher probability of death in comparison with patients with
ploidy score < 2.2.
Conclusion: According to the significance of the examined factor, survival was improved mainly
by the combination of surgery and chemotherapy, and the presence of low DNA ploidy score.
Background
Carcinoma of the pancreas is a very aggressive tumor, pos-
ing the fourth leading cause of cancer-related death in the
United States [1,2]. Most patients with pancreatic ductal
adenocarcinoma present with locally advanced or meta-
static disease on diagnosis, despite the availability of
advanced imaging techniques. Only 10–20% of cases are
candidates for curative surgery [3-5] and in these cases, the
reported 5-year survival rate ranges between 11% and
25% [6-8] as persistence or recurrence of regional disease
is reported in approximately 80% of patients following
curative resection [9]. Subsequently, surgery for pancreatic
cancer plays frequently a palliative role, to cure jaundice,
obstruction or pain [10]. Surgical palliation on the other
hand appears to be associated with a higher rate of early
complications and possibly a higher rate of procedure
related mortality [11], while stents may become
obstructed causing recurrent jaundice [12].
To improve the prognosis of patients with pancreatic can-
cer, it is essential to provide non-surgical treatment
options, such as systemic chemotherapy or targeted ther-
apy [13]. Systemic chemotherapy for pancreatic cancer
has proven of limited value because of the low response
rates and the severe adverse effects. Patients suitable for
chemotherapy should, therefore, be carefully selected on
the basis of specific prognostic factors. Several studies
have reported various pre- and postoperative factors as
determinants of short- and long-term survival in patients
undergoing surgery, but little is known about prognostic
indices for survival in patients with unresectable disease
[14-26].
The influence of DNA content on prognosis in adenocar-
cinomas of the pancreas has been investigated occasion-
ally, and the results are controversial. The findings
published in the literature, suggest that additional studies
are required to obtain the prognostic impact of DNA con-
tent in pancreatic cancer [27].
In a previously published study by our group we have
identified a number of factors which had independent
impact on survival including tumor localization, metas-
tases, PS, jaundice, weight loss, CRP, raised CEA and CA-
19.9, palliative surgery and chemotherapy [28]. In the
present study we update our patient cohort with the addi-
tion of a new laboratory parameter, DNA content.
Methods
Patients and data sources
The medical records of 226 patients between 1997 and
2003, with a histological diagnosis of pancreatic adeno-
carcinoma, from five Greek general hospitals were retro-
spectively reviewed. All had advanced unresectable
pancreatic adenocarcinoma. For the diagnosis of distant
metastasis, various imaging modalities were used, includ-
ing chest X-ray, ultrasonography and computed tomogra-
phy. Pathological confirmation of ductal adenocarcinoma
was obtained by surgery or a fine-needle aspiration biopsy
(FNAB). Survival time was calculated from time of diag-
nosis to death due to pancreatic cancer-related complica-
tions. Records with complete data (for the parameters
used as prognostic factors) were included in the analysis.
This protocol has been approved (ID:6443, 15/03/2004)
by the National and Kapodistrian University of Athens
human research ethics committee.
Prognostic variables
Twenty-two possible prognostic variables were selected,
based on factors identified by previous studies [6-8,14-
26,28] (Table 1). Histopathological grading was based on
the WHO system [29]. Patients were staged according to
the International Union Against Cancer TNM classifica-
tion [30].
For the evaluation of continuous biochemical parameters
we used group categorisations: for C-reactive protein
(CRP) normal <5 mg/dL, elevated: 5–15 mg/dL, >15 mg/
dL); for cancer antigen 19-9 (CA 19-9); patients with val-
ues ≤ 30 × nl vs >30 × nl; for carcinoembryonic antigen
(CEA) normal ≤ 5 mg/dL and elevated >5 mg/dL; for amy-
lase: yes and no; for hypoalbuminaemia: yes and no; for
diabetes: yes and no. Anemia, before initiation of any
therapy, was presented in two groups; severe (patients
received blood transfusion), and moderate (patients
received therapy with epoetin). For clinical parameters
similar categorisations were used. For therapy: palliative
surgery followed by chemotherapy, surgery only, chemo-
therapy only, supportive care only; for performance status
(PS): ≥90, = 80, = 70, = 60 and ≤50; for jaundice: yes and
no; for thrombophlebitis: yes and no; for steatorrhoea: yes
and no; for weight loss: none, 1–5%, 6–10% and >10% of
the total body weight. Pain was graded as follows: grade 0:
absence of pain, grade 1: palliation with common analge-
sics (paracetamol, NSAIDs), grade 2: controlled with theBMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
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use of opioids (fentanyl or morphine), grade 3: does not
remit completely despite the use of opioid analgesics. For
location of cancer: head, body and back (tail) of pancreas;
for primary tumor extent: tumor < 2 cm confined to the
pancreas, tumor > 2 cm confined to the pancreas, invasion
of adjacent tissues by tumor, invasion of adjacent organs
and for distant metastasis: yes and no. For ploidy score,
group categorisation was also applied: <2.2, 2.2–3.6, >3.6.
DNA Measurements (Ploidy)
The nuclei of Feulgen-stained cells were evaluated for
DNA ploidy using a Nikon eclipse microscope (Nikon,
Japan) connected with a Nikon CCD videocamera and an
IBM Pentium 4/PC with the appropriate Cell Measure-
ment Software (Image Pro Plus v. 5.1, Media Cybernetics
Inc, Silver Springs, MD, USA). A total of 100–200 nuclei
with clear boundaries appearing to have no loss of mem-
brane integrity were identified for analysis from each tis-
sue sample. Measurements were made using a
magnification of ×200. This analysis configuration per-
mits operator-dependent selection and measurement of
DNA content (Figures 1 and 2). This cell measurement
system was calibrated before each analysis session using a
slide with human normal lymphocytes with known DNA
content. The data generated were downloaded to standard
software packages for final analysis. DNA histograms were
categorized as diploid if the histogram presented a single
peak (2c; c = haploid DNA content) in the G0–G1 area
and the cell nuclei population did not exceed 10% in the
G2 region (4c). A sample was considered aneuploid if
clear aneuploid peaks (3c, 5c, 7c and 9c) were present. For
each case, coefficient of variance (CV) and DNA index/
ploidy score was calculated relative to internal controls
(lymphocytes; DI = 0.1) A ploidy score between 0.9 and
1.1 was considered diploid, aneuploid 1.1–1.4, triploid
1.4–1.8, tetraploid 1.8–2.2, hypertetraploid >2,2.
Statistical analysis
Descriptive statistics are calculated with the measures of
means, medians and standard deviation for quantitative
Table 1: Demographic and clinical variables in the study 
population (n = 226)
Variable Labels n %
Gender Males 132 61.4
Females 83 38.6
Age ≤ 60 87 40.5
60+ 128 59.5
PS ≥ 90 25 11.1
= 80 75 33.2
= 70 74 19.5
= 60 40 17.7
≤ 50 42 18.6
Location Head 147 68.4
Body 52 24.2
Back ('tail") 16 7.4
Therapy Chemotherapy and surgery 53 24.7
Chemotherapy only 65 30.2
Surgery only 24 11.2
None 73 34.0
Surgery Yes 77 35.8
No 138 64.2
Chemotherapy Yes 118 54.9
No 97 45.1
Ploidy < 2.2 20 8.8
2.2–3.6 86 38.1
>3.6 120 53.1
Amylase Yes 23 10.7
No 192 89.3
Grading High 14 6.5
Medium 187 87.0
Low 14 6.5
Primary tumor extent 1 15 7.0
26 0 2 7 . 9
37 7 3 5 . 8
46 3 2 9 . 3
CEA ≤ 5 mg/dL 72 33.5
>5 mg/dL 143 66.5
CA 19-9 ≤ 30 × normal 30 14.0
>30 × normal 185 86.0
Thrombophlebitis Yes 105 48.8
No 110 51.2
Diabetes Yes 199 92.6
No 16 7.4
CRP Normal 150 69.8
Increased 35 16.3
Greatly increased 30 14.0
Steatorrhoea Yes 99 46.0
No 116 54.0
Albumin Yes 114 53.0
No 101 47.0
Epoetin Yes 36 16.7
No 179 83.3
Transfusion Yes 61 28.4
No 154 71.6
Weight loss None 62 28.8
1–5% 31 14.4
6–10% 58 27.0
>10% 64 29.8
Pain None 50 23.3
Pain 1 84 39.1
Pain 2 55 25.6
Pain 3 26 12.1
Metastases None 86 40.0
LN 37 17.2
LIV 7 3.3
AB 29 13.5
LN-AB 30 14.0
LIV-LN-AB 26 12.1
Jaundice Yes 46 21.4
No 169 78.6
AB, abdominal metastasis; CA 19-9, cancer antigen 19-9; CEA, 
carcinoembryonic antigen; CRP, C-reactive protein; LIV, liver 
metastasis; LN, lymph node metastasis; 1: tumor < 2 cm confined to 
the panreas, 2: tumor > 2 cm confined to the pancreas, 3: invasion of 
adjacent tissues by tumor, 4: invasion of adjacent organs.
Table 1: Demographic and clinical variables in the study 
population (n = 226) (Continued)BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
Page 4 of 11
(page number not for citation purposes)
parameters and counts/percentages for discrete factors.
Overall survival is studied with the use of Kaplan Meier
method. Survival differences between groups are studied
with the use of Log-rank test. A Multivariate Cox regres-
sion model was implemented to study the simultaneous
effect of parameters on survival after taking into account
the parallel effect of remaining factors. Best model selec-
tion was based on manual and automated forward tech-
niques. Results of regression analyses are displayed in the
form of regression estimates tables. Hazard ratios of out-
comes under study are calculated for each parameter esti-
mate as well as 95% confidence intervals. Categorical
covariates are compared with a predefined reference cate-
gory.
All analyses are performed at a significance level of α =
0.05 with the use of the statistical package SPSS 12.0.
Results
Patients
Two hundred and twenty six records of patients with his-
tologicaly confirmed pancreatic carcinoma entered the
analysis. Their Median age was 62.5 years (range 32–76,
median 63.0 and standard deviation: 7.76 years) and the
Median PS (Karnofsky) was 70 (range 40–100). Palliative
surgery was performed in 52.7% of patients, while 62.9%
received chemotherapy for advanced disease. The fre-
quencies of the clinical variables are shown in Table 1.
Despite the fact that authors included in the present study
derived from 5 different institutions, it should be stressed-
out that all patients during the study period were treated
by General Surgeons derived from "Laikon" General Hos-
pital, and all three Medical Oncologists participating in
the present study were again affiliated at the same institu-
tion (except C.K. who joined "Metaxa" Cancer Hospital
after October 2001), and more importantly applied the
same therapeutic protocols/algorithms. These treatment
algorithms evolved over time in accordance to interna-
tionally accepted standards and guidelines with respect to
advanced pancreatic cancer. From 1997–2000 a combina-
tion of 5FU-Leucovorin (LV)-Epirubicin-Mitomycin
(FEMLV) was applied at 1st-line followed by single-agent
Gemcitabine or the combination of Gemcitabine/CPT11
as 2nd-line. From 2001–2003, single-agent Gemcitabine
was administered at 1st-line and Oxaliplatin-5FU-LV at
relapse as 2nd-line chemotherapy.
Survival analysis
Survival data were collected for all patients. Four patients
were alive at the end of the study, and their survival time
was censored. Based on Kaplan-Meier method, mean sur-
vival time was recorded at 38.41 weeks (95% c.i.: 33.17–
43.65), median survival: 27.00 weeks (95% c.i.: 23.18–
30.82).
Univariate analysis
In the univariate analysis, all variables were related to the
survival outcome at a significance level of alpha = 10%,
apart from gender, age and CA19-9 (Table 2).
DNA index 1.9 (A) versus DNA index 4.4 (B) as derived by subsequent image analysis of pancreatic tumor specimens (Feulgen  staining, 200×) Figure 1
DNA index 1.9 (A) versus DNA index 4.4 (B) as derived by subsequent image analysis of pancreatic tumor 
specimens (Feulgen staining, 200×).BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
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Multivariate analysis
Prognostic factors found to have strongest significance of
a relation to survival according to the univariate analysis
were entered into the multivariate analysis model first
(Table 3). Factors were added and excluded using the
change in likelihood between models as inclusion and
exclusion criteria. Both manual and forward automated
procedures resulted in the same final model, which is
described in Table 3.
Hazard ratios of risk factors
Patients with PS 80 had 3.0 times lower probability of
death in comparison with patients with PS 50, and
patients with PS 90 had 3.9 times lower probability of
death in comparison with patients with PS 50. Patients
with distant metastases in lymph nodes, liver or the abdo-
men had 2.5 times higher probability of death in compar-
ison with patients without. Patients at local extension of
the tumor stage 2 had 2.8 times higher probability of
death in comparison with patients at stage 1. Patients with
with moderate anaemia under epoetin therapy had 1.5
times lower probability of death in comparison with
patients without. Patients with weight loss 1–5% or 5–
10% of body weight had 3.0 times lower probability of
death in comparison with patients with weight loss >
10%. Patients with steatorrhoea had 1.8 times higher
probability of death in comparison with patients without.
Patients with CEA > 5 mg/dL had 1.4 times higher proba-
bility of death in comparison with patients with CEA < 5
mg/dL. Patients with moderate pain had 2.1 times lower
probability of death in comparison with patients with
severe pain. Patients with ploidy score 2.2–3.6 had 6.3
Representative snapshot from image analysis screen (DNA ploidy) Figure 2
Representative snapshot from image analysis screen (DNA ploidy). Nuclei are semiautomatically circumscribed and 
measured.BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
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times higher probability of death in comparison with
patients with ploidy score < 2.2. Patients with ploidy score
> 3.6 had 5.0 times higher probability of death in compar-
ison with patients with ploidy score < 2.2 (Figure 3).
Patients with only chemotherapy had 4.2 times lower
probability of death in comparison with patients without
any treatment. Patients with chemotherapy and surgery
had 6.7 times lower probability of death in comparison
with patients without any treatment (Figure 4).
Discussion
The majority of patients with pancreatic cancer are not eli-
gible for surgery at presentation because the disease only
becomes symptomatic at late stages. Therefore, predictive
factors for patients presenting with unresectable, locally
recurrent or metastatic disease should be considered when
selecting appropriate treatment for each individual
patient [6,21-23,25].
The prognostic value of DNA ploidy in pancreatic carci-
noma has been studied in the past and results have been
disappointing [27]. The first reported evaluation of DNA
nuclear pattern in pancreatic cancer was in 1987 by Weger
et al who used flow cytometry to examine 77 cases of duc-
tal carcinoma [31]. There were no diploid tumor tumors
and all patients (n = 16) with triploid neoplasms died
within 18 months. In contrast, of 15 patients with near
tetraploid tumors, 8 were alive at 70 months after the time
of diagnosis. Since then, a number of studies have
reported conflicting results in terms of prognostic value of
these techniques in pancreatic cancer. Bottger et al exam-
ined DNA content in 41 cases following resection using
image cytometry [32].
Hypotriploid (n = 1), triploid (n = 7), hypertriploid (n =
21), and tetraploid (n = 12) patterns were noted. Tetra-
ploid tumors had a significantly improved survival versus
non-tetraploid tumors (p = 0.0037). They found that
DNA ploidy was the strongest independent prognostic
factor for survival in these patients by multivariate analy-
sis. Yeo et al determined DNA content by image cytometry
and found that 43% of 119 tumors were diploid and 57%
were aneuploid. Patients with diploid tumors had a
median survival of 24 months and 5-year survival of 39%,
significantly better than the median survival of 11.5
months and 5-year survival of 8% observed in patients
with aneuploid tumors; p = 0.0002. In multivariate anal-
ysis DNA content was one of the strongest independent
predictors of favourable outcome in pancreatic cancer
[33]. Porschen et al determined DNA content by flow
cytometry and found that 29 of 56 (52%) pancreatic duc-
tal adenocarcinomas were diploid, while 27 (48%) were
aneuploid. The median survival of those with diploid
tumors was 6.9 months as compared to 4.5 months for
aneuploid tumors (p = 0.013), but this survival benefit
was seen mostly in patients who underwent nonradical
surgical intervention. In multivariate analysis, the only
factors associated with survival were radicality of surgery
Table 2: Univariate analysis of survival time by categorical variable
Parameter Log-rank
Test value
Degrees of Freedom P
Gender 1,79 1 0,1811
Age (years) 0,34 1 0,5586
PS 229,07 4 <0.001
Location 10,60 2 <0.005
Grading 15,22 2 <0.005
Primary tumor extent 40,90 3 <0.001
Distant Metastasis 38,80 1 <0.001
Ploidy-group 93,79 2 <0.001
Epoetin 9,16 1 0.003
Blood Transfusion 22,64 1 <0.001
Weight loss 178,78 3 <0.001
Pain 79,81 3 <0.001
Jaundice 6,49 1 0.01
Thrombophlebitis 16,87 1 <0.001
Diabetes 4,36 1 0.04
Steatorrhoea 37,96 1 <0.001
CEA 37,51 1 0.001
CA 199 1,13 1 <0.001
Amylase 6,43 1 0.01
CRP 6,95 2 0.03
Albumin 54,78 1 <0.001
Therapy 161,48 3 <0.001
PS: Performance Status; CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9; CRP, C-reactive protein.BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
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and DNA ploidy. The authors concluded that DNA ploidy
adds valuable information which is distinct from other
clinico-pathological variables [34]. Similar results have
been reported by others [35-39]. In contrast, Baisch et al
using flow cytometry analysis did not find DNA ploidy to
be a prognostic factor for survival [40]. They did note that
aneuploidy (15%) of their cases was associate with
advanced stage and tended to be more common in high
grade tumors. Herrera et al examined a cohort of 72
patients who underwent radical resection at the Mayo
Clinic between 1951 and 1980 [41]. The patients with
short (mortality within 12 months) and long term sur-
vival (>3 years) were examined. No difference in the DNA
nuclear histograms, the fraction of cells in the S phase or
DNA index was noted between these two groups. Simi-
larly, in a recently published study, Stoecklein et al
reported their results of DNA ploidy in conjunction to
HER2 amplification and chromosome 17 copy number
analysis in patients with pancreatic ductal adenocarci-
noma after radical operation (R0 resection). Tumor
ploidy levels correlated with prognosis of patients with
pancreatic ductal adenocarcinoma, in contrast, to the
absence of a prognostic effect on patient outcome regard-
ing HER2 gene amplification or p185 (HER2) overexpres-
sion [42]. Berczi et al also concluded using flow cytometry
analysis that DNA ploidy status had no significant effect
on survival of patients with carcinoma of the pancreatic
head region [43]. To some extend, disparate results in
DNA ploidy studies have been ascribed to the differing
techniques employed, and the heterogeneity in the
nuclear DNA content in pancreatic tumor cells, hence
image cytometry has generally been considered superior
to flow cytometry as only tumor cells are used for DNA
measurement [34]. Subsequently, the clinical utility of
DNA ploidy has been limited and its role in staging and
treatment is still under investigation [27].
In the present study all factors under investigation were
significantly related to survival time except gender, age,
and CA-19.9, which is largely in accordance with results
Table 3: Final Cox proportional odds regression model
Variable B SE Wald p Hazard ratio 95,0% CI for Exp(B)
Lower Upper
PS(60 vs ≤ 50) ,376 ,268 1,966 ,161 1,456 ,861 2,461
PS(70 vs ≤ 50) -,501 ,319 2,467 ,116 ,606 ,324 1,132
PS(80 vs ≤ 50) -1,180 ,345 11,676 ,001 ,307 ,156 ,605
PS(90 vs ≤ 50) -1,357 ,420 10,437 ,001 ,257 ,113 ,586
PRIMARY EXTENT(4 vs 1) ,085 ,489 ,030 ,862 1,088 ,418 2,836
PRIMARY EXTENT (3 vs 1) ,399 ,495 ,649 ,420 1,491 ,564 3,936
PRIMARY EXTENT (2 vs 1) 1,015 ,518 3,838 ,050 2,758 1,000 7,610
DISTANT METASTASES (yes vs no) ,949 ,247 14,730 ,000 2,583 1,591 4,194
PLOIDY (3.6+ vs <2.2) 1,605 ,341 22,093 ,000 4,975 2,548 9,714
PLOIDY (2.2–3.6 vs <2.2) 1,846 ,375 24,251 ,000 6,333 3,038 13,201
EPOETIN – ANEMIA (yes vs no) -,441 ,184 5,779 ,016 ,643 ,449 ,922
WEIGHT LOSS (none vs 10+) -,536 ,379 1,997 ,158 ,585 ,278 1,230
WEIGHT LOSS (1–5% vs 10+) -1,081 ,330 10,719 ,001 ,339 ,178 ,648
WEIGHT LOSS (5–10% vs10+) -1,097 ,268 16,756 ,000 ,334 ,197 ,565
PAIN (none vs severe) -,360 ,355 1,028 ,311 ,698 ,348 1,399
PAIN (light vs severe) -,224 ,286 ,613 ,434 ,799 ,456 1,400
PAIN (moderate vs severe) -,769 ,281 7,486 ,006 ,463 ,267 ,804
STEATORIA (yes vs no) ,585 ,183 10,185 ,001 1,795 1,253 2,572
CEA (>5 vs <= 5) ,345 ,161 4,586 ,032 1,413 1,030 1,938
THERAPY (CT vs none) -1,449 ,272 28,445 ,000 ,235 ,138 ,400
THERAPY (Surgery vs none) -,416 ,254 2,669 ,102 ,660 ,401 1,087
THERAPY(both vs none) -1,903 ,270 49,641 ,000 ,149 ,088 ,253
PS, Performance Status; CEA, carcinoembryonic antigen; CT, Chemotherapy.BMC Cancer 2009, 9:264 http://www.biomedcentral.com/1471-2407/9/264
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previously published by our group and others [28]. We
distinguished three groups of factors that influence sur-
vival. The first group of factors relates to the presence of
disease. Patients with distant metastasis and/or locally
extensive disease had a worse prognosis. Patients with
increased ploidy score and/or increased levels of the
marker CEA, which represent increased tumor burden,
were also associated with a worse prognosis. The second
group of factors relates to the clinical characteristics of the
patient and the immune response such as poor PS at the
time of diagnosis, weight loss, severity of pain, steator-
rhoea, and anaemia under epoetin-A therapy. Each of
these factors was related to a negative influence on sur-
vival. The third group of factors relates to therapeutic
modalities: patients given only supportive care had the
worst survival in comparison to those who underwent
chemotherapy and better with the combination of chem-
otherapy and surgery.
According to the significance of the examined factor, sur-
vival was improved mainly by the combination of surgery
and chemotherapy, and by a low DNA ploidy score. Sec-
ondary factors are the performance status (performance
status and weight loss) and expansion of cancer (local
extension and distant metastases). Considerable factors
are pain, anemia, steatorrhoea, and CEA value.
The present study represents a comprehensive analysis
regarding the prognostic significance of microscopically
assessed DNA ploidy in the context of additional patient-
and treatment-related known prognostic factors in a large
cohort of advanced inoperable ductal pancreatic adeno-
carcinoma. Our analysis demonstrated that DNA ploidy,
Survival data according to tumor ploidy Figure 3
Survival data according to tumor ploidy.
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together with chemotherapy or surgery or surgery plus
chemotherapy carry the most significant independent
effect on outcome of advanced pancreatic adenocarci-
noma.
Conclusion
In conclusion, we assessed factors that are related to the
outcome of patients with advanced, unresectable ductal
pancreatic adenocarcinoma. The determination of DNA
content of pancreatic cancer cells provides additional
prognostic information and should be considered along
with other established prognostic factors for the develop-
ment of effective multidisciplinary treatment strategies
and the design of future clinical trials. In terms of treat-
ment modality our study reinforces the notion that the
main factor, which may affect survival in patients with
pancreatic cancer is therapy, and so all patients, unless
contraindicated, should be offered palliative surgery and
chemotherapy, or chemotherapy alone if the tumor is
considered unresectable.
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